Your browser doesn't support javascript.
loading
BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer / 中国癌症杂志
China Oncology ; (12): 750-755, 2016.
Article in Chinese | WPRIM | ID: wpr-501608
Responsible library: WPRO
ABSTRACT
Background and

purpose:

Breast cancer has the highest morbidity and mortality rate in women worldwide. Triple-negative breast cancer (TNBC) has no speciifc target and has low survival rate. Recent studies have veriifed BRD4 could promote tumor progression. This study aimed to detect the expression level of BRD4 in TNBC after treatment with gemcitabine, and to reveal the effect ofBRD4 silencing plus gemcitabine as a treatment for TNBC.

Methods:

The expression ofBRD4 in TNBC cell lines treated with gemcitabine was detected by reverse transcription PCR (RT-PCR) and Western blot. The effect of BRD4 silencing plus gemcitabine in TNBC was illustratedin vitro and in vivo.

Results:

The expression ofBRD4 in TNBC was signiifcantly increased after treatment with gemcitabine.In vitro,BRD4 knockdown signiifcantly lowered the IC50 value. The apoptotic rate of TNBC was signiifcantly increased in theBRD4 silencing plus gemcitabine group compared to the other. The growth rate of tumorin vivo was signiifcantly lowered in the BRD4 silencing plus gemcitabine group.

Conclusion:

BRD4 may play an important role in the drug resistance to gemcitabine in TNBC.BRD4 silencing plus gemcitabine may be a novel treatment strategy for TNBC.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: China Oncology Year: 2016 Type: Article
Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: China Oncology Year: 2016 Type: Article